Marta Casal Moura, MD, MSc, MSPH, began her one-year Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship in July 2022. For anti-neutrophil autoantibody (ANCA)-associated vasculitis (AAV), she is studying the predictors of response to plasma exchange in patients who have AAV glomerulonephritis and how histologic scores can predict the response…...
Introducing Our 2022-2023 VCRC-VF Fellow: Mohanad M. Elfishawi, MBBCh, MS
Mohanad M. Elfishawi, MBBCh, MS, began his one-year Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship on January 1, 2022. Dr. Elfishawi will be working on several projects in giant cell arteritis (GCA) including investigating metabolic risk factors for GCA. In addition, he plans to study aortic involvement in patients with…...
Recruiting: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week…...
- 1
- 2